Impact of prophylaxis on health-related quality of life of boys with hemophilia: an analysis of pooled data from 9 countries, Res Pract Thromb Haemost, vol.3, pp.397-404, 2019. ,
Treatment adherence in hemophilia, Patient Prefer Adherence, vol.11, pp.1677-1686, 2017. ,
Extended half-life factor VIII and factor IX preparations, Transfus Med Hemother, vol.45, pp.86-91, 2018. ,
Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics, Crit Rev Biotechnol, vol.35, pp.235-254, 2015. ,
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias, Drug Des Devel Ther, vol.8, pp.365-371, 2014. ,
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A, Blood, vol.123, pp.317-325, 2014. ,
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients, Blood, vol.119, pp.3031-3037, 2012. ,
Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A, Haemophilia, vol.22, pp.72-80, 2016. ,
Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A, J Thromb Haemost, vol.13, pp.967-977, 2015. ,
Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study, Haemophilia, vol.26, pp.494-502, 2020. ,
Real-life experience in switching to new extended half-life products at European haemophilia centres, Haemophilia, vol.25, pp.946-952, 2019. ,
The effect of switching to rFVIIIFc on treatment patterns and annualised bleed rate before and after: a within-patient comparison from the UK National Haemophilia Database, Haemophilia, vol.24, pp.3-196, 2018. ,
Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience, Blood Transfus, vol.2019, pp.1-11 ,
Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B, Haemophilia, vol.24, pp.414-419, 2018. ,
the IgG Fc Immune Tolerance Group. Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia, Blood, vol.131, pp.2205-2214, 2018. ,
Haptens bound to self IgG induce immunologic tolerance, while when coupled to syngeneic spleen cells they induce immune suppression, Immunol Rev, vol.50, pp.71-104, 1980. ,
The use of haptenated immunoglobulins to induce B cell tolerance in vitro. The roles of hapten density and the Fc portion of the immunoglobulin carrier, J Immunol, vol.131, pp.2204-2209, 1983. ,
Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function, Eur J Immunol, vol.16, pp.1013-1016, 1986. ,
Expansion of CD4 + CD25 + regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis, Blood, vol.111, pp.715-722, 2008. ,
Epitope-specific tolerance induction with an engineered immunoglobulin, Proc Natl Acad Sci U S A, vol.93, pp.5019-5024, 1996. ,
Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function, J Immunol, vol.179, pp.5571-5575, 2007. ,
Activation of natural regulatory T cells by IgG Fc-derived peptide, Tregitopes". Blood, vol.112, pp.3303-3311, 2008. ,
Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein, Biologicals, vol.43, pp.213-219, 2015. ,
Identification of FIXa-and FXspecific antibodies for the generation of bispecific antibodies with FVIIIa-like activity, Res Pract Thromb Haemost, vol.1, pp.1-1451, 2017. ,
US Guidelines for immune tolerance induction in patients with haemophilia A and inhibitors, Haemophilia, vol.21, pp.559-567, 2015. ,
Factor VIII inhibitors in hemophilia A: rationale and latest evidence, Ther Adv Hematol, vol.4, pp.59-72, 2013. ,
Immunogenicity of long-lasting recombinant factor VIII products, Cell Immunol, vol.301, pp.40-48, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01292437
Inhibitors in haemophilia: what have we learned from registries? A systematic review, J Intern Med, vol.277, pp.1-15, 2015. ,
Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins, Blood, vol.105, pp.4865-4870, 2005. ,
Materno-fetal transfer of preproinsulin through the neonatal Fc receptor prevents autoimmune diabetes, Diabetes, vol.64, pp.3532-3542, 2015. ,
Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance, Sci Transl Med, vol.7, pp.275-296, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02425481
Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice, Cell Immunol, vol.301, pp.30-39, 2016. ,
Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization, Blood Adv, vol.2, pp.2904-2916, 2018. ,
Reduction of factor VIII inhibitor titers during immune tolerance induction with recombinant factor VIII-Fc fusion protein, Pediatr Blood Cancer, vol.63, pp.922-924, 2016. ,
Extended half-life factor VIII for immune tolerance induction in haemophilia, Haemophilia, vol.22, pp.552-554, 2016. ,
Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis, Haemophilia, vol.25, pp.789-796, 2019. ,
Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein for in hemophilia A patients with inhibitors in Japan: observational Fc Adolescent and Children Treatment Study (FACTs) first interim reports, Res Pract Thromb Haemost, vol.3, pp.1-891, 2019. ,
Outcome of immune tolerance induction using an extended half-life clotting factor concentrate-recombinant factor VIII Fc (Eloctate?)-a report from India, Blood, vol.132, p.2494, 2018. ,
Real-world data of immune tolerance induction (ITI) using recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with severe hemophilia A with inhibitors at high risk for ITI failure, Haemophilia, vol.25, pp.3-77, 2019. ,
rFVIIIFc for first-time immune tolerance induction (ITI) therapy: interim results from the global, prospective verITI-8 study, of the International Society on Thrombosis and Haemostasis (ISTH), 2019. ,
,
Study design for reitirate-a prospective study of rescue ITI with recombinant factor VIII Fc (rFVIIIFc) in patients who have failed previous ITI attempts, Haemophilia, vol.24, pp.32-135, 2018. ,
Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-a retrospective analysis, Haemophilia, vol.24, pp.245-252, 2018. ,
Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein, Haemophilia, vol.22, pp.462-464, 2016. ,
Incidence of inhibitors in previously untreated patients with severe haemophilia A treated with rFVIIIFc: the PUPs A-LONG study, Haemophilia, vol.25, pp.25-34, 2019. ,
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, J Thromb Haemost, vol.2, pp.1047-1054, 2004. ,
Marijke van den Berg H. Treatmentrelated risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study, Blood, vol.109, pp.4648-4654, 2007. ,
A randomized trial of factor VIII and neutralizing antibodies in hemophilia A, N Engl J Med, vol.374, pp.2054-2064, 2016. ,
Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance, Expert Rev Hematol, vol.7, pp.747-755, 2014. ,
The national blueprint for future factor VIII inhibitor clinical trials: NHLBI State of the Science (SOS) Workshop on factor VIII inhibitors, Haemophilia, vol.25, pp.581-589, 2019. ,
Haemophilia and joint disease: pathophysiology, evaluation, and management, J Comorb, vol.1, pp.51-59, 2011. ,
Bone density in haemophilia: a single institutional cross-sectional study, Haemophilia, vol.20, pp.121-128, 2014. ,
Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia, Haemophilia, vol.15, pp.559-565, 2009. ,
Epidemiology of fractures in patients with haemophilia, Injury, vol.46, pp.1885-1890, 2015. ,
Increased fracture rates in people with haemophilia: a 10-year single institution retrospective analysis, Br J Haematol, vol.170, pp.584-586, 2015. ,
Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis, Blood Rev, vol.35, pp.43-50, 2019. ,
Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein, Haemophilia, vol.24, pp.77-84, 2018. ,
Improved hemostasis and joint health over time in a subset of patients who did not reach optimal hemostatic control in the first year of recombinant factor VIII Fc fusion protein (rFVIIIFc) therapy, Res Pract Thromb Haemost, vol.3, pp.1-189, 2019. ,
Improvements in joint health during long-term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A, Haemophilia, vol.25, pp.1-154, 2019. ,
Joint bleeding tendencies in adult patients with hemophilia: it's not all pharmacokinetics, Clin Appl Thromb Hemost, vol.25, p.1076029619862052, 2019. ,
Recombinant factor VIII Fc fusion protein inhibits inflammatory osteoclast formation in vitro, Res Pract Thromb Haemost, vol.3, pp.1-228, 2019. ,
How to cite this article: Meeks S, Lacroix-Desmazes S. Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy, Haemophilia, vol.135, pp.1-8, 2020. ,